عرض بسيط للتسجيلة

المؤلفOnitilo, Adedayo A.
المؤلفPiwuna, Tinuade O.
المؤلفIslam, Nazmul
المؤلفFuruya-Kanamori, Luis
المؤلفKumar, Sanjay
المؤلفDoi, Suhail A.R.
تاريخ الإتاحة2023-02-22T05:47:56Z
تاريخ النشر2022-03-01
اسم المنشورClinical Medicine and Research
المعرّفhttp://dx.doi.org/10.3121/cmr.2021.1693
الاقتباسOnitilo AA, Piwuna TO, Islam N, Furuya-Kanamori L, Kumar S, Doi SAR. Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy. Clin Med Res. 2022 Mar;20(1):16-22. doi: 10.3121/cmr.2021.1693.
الرقم المعياري الدولي للكتاب15394182
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85128489433&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/40262
الملخصObjective: Within the last decade, the use of ibrutinib, a first-generation, non-selective, irreversible Burton's tyrosine kinase inhibitor for the treatment of hematological malignancies has proven highly effective in improving patient outcomes.Background: Ibrutinib has been associated with an increase in atrial fibrillation (AF). The predisposing factors are thought to be pre-existing cardiovascular risk factors, but these have not been directly evaluated.Methods: We conducted a nested case-control study, recruiting consecutive ibrutinib treated subjects to evaluate cardiovascular risk factors associated with the development of AF in patients diagnosed with hematological B-cell malignancies.Results: Of the 189 patients treated with ibrutinib and without AF at baseline, 54 (29%) developed AF. Cardiovascular risk factors associated with AF development were, older age, prior hypertension (HTN), history of heart failure (HF) and congenital heart disease. A patient with HF at baseline had a 1,2, 6, and 12 month cumulative hazard of AF of 40%, 48%, 64%, and 71%, respectively. Patients with prior HTN without HF at baseline had a 1,2, 6, and 12 month cumulative hazard of AF of 5%, 10%, 23%, and 31%, respectively while on ibrutinib therapy.Conclusions: The relationship between ibrutinib, cardiovascular comorbidities, and AF is through pre-existing cardiovascular disease. An individualized, multidisciplinary approach involving cardiologists should be considered when initiating ibrutinib, particularly when there is a history of HTN, HF or congenital heart disease. In such patients, there should be close cardiovascular monitoring and prompt intervention when AF develops to improve patient outcomes.
اللغةen
الناشرMarshfield Clinic
الموضوعAtrial fibrillation
B-cell malignancies
Bruton’s tyrosine kinase
Hematological malignancies
Ibrutinib
Risk factors
العنوانDeterminants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy
النوعArticle
الصفحات16-22
رقم العدد1
رقم المجلد20
ESSN1554-6179
dc.accessType Full Text


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة